Efficacy of direct-acting antivirals in patients with HCV-associated cryoglobulinemia and monoclonal gammapathy

Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals.

BACKGROUND & AIMS Cryoglobulins (circulating immune complexes of polyclonal IgG, monoclonal IgM, and rheumatoid factor) are detected in the circulation of 40% to 60% of patients with chronic hepatitis C virus infection, and cryoglobulinemic vasculitis (CV) is observed in approximately 10% of patients. We aimed to assess the clinical and immune effects of direct-acting antiviral treatment. MET...

Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.

Among the 170 million HCV-infected subjects worldwide (around 34 million) HCV-G4 accounts for approximately 20% of those infected. This population accounts for most new infections, with limited access to therapy. While in the US HCV-G4 is responsible for 1–2% of HCV infection, in the Middle East and Sub-Saharan African regions it is the main cause of HCV infection, with Southern Europe also det...

HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.

BACKGROUND Application of response-guided therapy (RGT) rules to the treatment of HCV infection with pegylated interferon-α2a and ribavirin, and direct-acting antivirals (DAAs) such as the NS3/4A protease inhibitors (PIs) boceprevir and telaprevir, relies on the determination of viral genotype and on-treatment HCV RNA level. Currently there are few data available regarding the clinical impact o...

Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C

BACKGROUND There is a lack of evidence-based data on aged patients with newer direct-acting antivirals (DAAs) and with shorter duration of treatment regimens involving DAAs with or without ribavirin (RBV) and pegylated interferon (Peg IFN). PATIENTS AND METHODS Medical records of 240 patients treated with DAAs with or without Peg IFN and RBV between January 2013 and July 2015 were retrospecti...

Direct-acting Antivirals Induce Lymphoproliferative Disease Response in HCV-infected Patients: A Prospective Case Series